Skip to main content

Advertisement

Table 1 Baseline characteristics (intention to treat population)

From: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

  SOX (n = 168) CapeOX (n = 172)
Primary site   
  Colon 109 (65%) 108 (63%)
  Rectum 59 (35%) 64 (37%)
Sex   
  Male 109 (65%) 102 (59%)
  Female 59 (35%) 70 (41%)
Age   
  ≤65 years 121 (72%) 126 (73%)
  >65 years 47 (28%) 46 (27%)
ECOG performance status   
  0-1 164 (98%) 168 (98%)
  2 4 (2%) 4 (2%)
Previous (neo)adjuvant therapy   
  Yes 37 (22%) 38 (22%)
  No 131 (78%) 134 (78%)
Site of metastasis   
  Liver metastasis 105 (63%) 111 (65%)
  Non-liver metastasis 63 (37%) 61 (35%)
Number of metastatic organs   
  One organ 65 (39%) 49 (29%)
  Two organs 61 (36%) 70 (41%)
  Three or more organs 42 (25%) 53 (31%)
Measurability   
  Measurable lesions 155 (92%) 155 (90%)
  Assessable lesions only 13 (8%) 17 (10%)